A Phase 1 interventional study of SMS995 and Placebo in Irritable Bowel Syndrome (IBS), sponsored by Novartis. Completed at 7 sites in 4 countries. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-05-08.
Sponsored by Novartis · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Irritable Bowel Syndrome with a site in United Kingdom — 7 open to participants now, 8 under way, none of them phase 3. Irritable Bowel Syndrome · United Kingdom.
Among the 66 studies in Irritable Bowel Syndrome with a site in United Kingdom, this one is the 36th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2008, is the only one in phase 1, and was the 9th registered.
1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.
Browse Irritable Bowel Syndrome studies →7 of the 66 studies in Irritable Bowel Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United Kingdom, United States, Belgium and 7 more countries
Ages 18–75
Eli Lilly and Company · Sites in United Kingdom, United States, Belgium and 5 more countries
Ages 18–75
Hospital Universitari Vall d'Hebron Research Institute · Sites in United Kingdom, United States, Canada and 4 more countries
Ages 18–80 · Healthy volunteers
University of Nottingham · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Glenn Gibson · Sites in United Kingdom
Ages 18–60
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 70 across 898 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 71 across the 58 interventional studies, 120 across the 7 observational. Of the 50 that completed or were terminated, 12 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 66 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Novartis has 4 studies filed under Irritable Bowel Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Irritable Bowel Syndrome with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07916948University of RoehamptonEffects of Epetôme on Gastrointestinal Function, Inflammation and Wellbeing in Adults With IBS-like Symptoms (EPEGUT) | 2027-01-15 |
| NCT07545772Eli Lilly and CompanyA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) | 2027-07 |
| NCT07545759Eli Lilly and CompanyA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 66 studies in Irritable Bowel Syndrome with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to provide information on feasibility and reproducibility of barostat assessments of colorectal sensory functions and compliance and their pharmacological modulation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SMS995
Drug: Placebo
Also known as: Octreotide, Sandostatin
- 5 sensory pressure thresholds [mmHg] from ascending method of limits (AML) barostat protocol. - 16 sensory intensity ratings from the random phasic distention (RPD) barostat protocol.
Time frame: throughout the study
- colorectal compliance
Time frame: throughout the study
The record gives a start of Jan 2008 and a primary completion of Apr 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Octreotide